探讨谷胱甘肽S移换酶π(GST-π)和P170糖蛋白，在紫杉醇联合顺铂治疗上皮性卵巢癌(EOC)后的表达及其临床意义。

选取2012年6月至2016年6月上海市普陀区妇婴保健院收治的60例EOC患者为研究对象。按照计算机随机数字表法，将其随机分为研究组及对照组，各为30例。研究组采取紫杉醇联合顺铂治疗，对照组单纯采取紫杉醇治疗。化疗后，统计学分析两组患者GST-π和P170糖蛋白阳性表达率、化疗疗效、血清学指标及不良反应发生率。研究组及对照组患者的年龄、国际妇产科联盟(FIGO)分期及EOC复发率等临床资料比较，差异均无统计学意义(P>0.05)。本研究遵循的程序符合上海市普陀区妇婴保健院人体试验委员会所制定的伦理学标准，得到该委员会批准，分组征得受试对象的知情同意，并与之签署临床研究知情同意书。

化疗后，研究组EOC患者GST-π及P170糖蛋白阳性表达率，均显著低于对照组，差异均有统计学意义(χ²＝4.28、4.34，P<0.05)；研究组EOC患者血清糖链抗原125(CA₁₂₅)、转化生长因子(TNF)-α及可溶性白细胞介素-2受体(SIL-2R)水平的改善程度，均显著优于对照组，差异均有统计学意义(t＝5.14、6.53、5.86，P<0.05)。研究组EOC患者的化疗总体不良反应发生率显著低于对照组，并且差异有统计学意义(χ²＝4.44，P<0.05)。研究组EOC患者的化疗总有效率显著高于对照组，差异亦有统计学意义(χ²＝5.52，P<0.05)。

紫杉醇联合顺铂治疗EOC的化疗敏感性高，不良反应发生率低，临床疗效高。但是，临床对于EOC化疗，是否可选择GST-π和P170糖蛋白作为随访化疗疗效的指标，尚需多中心、大样本随机对照试验进一步研究、证实。

To study expressions and clinical significances of the glutathione S-transferase π (GST-π) and P170 glycoprotein in paclitaxel combined with cisplatin in treatment of epithelial ovarian cancer (EOC).

From June 2012 to June 2016, a total of 60 cases of EOC patients who hospitalized and treated in Putuo District Maternal and Child Health Hospital of Shanghai were recruited in this study. They were randomly divided into research group (n=30, treated by paclitaxel combined with cisplatin) and control group (n=30, treated by paclitaxel alone) by random number table method.Positive expressions of GST-π and P170 glycoprotein, curative effects, serological indicators, and incidence of adverse reactions after chemotherapy between two groups were analyzed by statistical methods. There were no significant differences between two groups among age, Federation International of Gynecology and Obstetrics (FIGO) clinical stage and relapse rate of EOC (P>0.05). The procedure of this study was consistent with ethical standard established by the committee of investigation in human beings of Putuo District Maternal and Child Health Hospital of Shanghai. Patients were informed of grouping and their written informed consents were obtained before clinical studies.

After chemotherapy, positive expressions of GST-π and P170 glycoprotein in research group were remarkably lower than those in control group, and there were significant differences (χ²=4.28, 4.34; P<0.05). The levels improvement degrees of serological indicators such as carbohydrate antigen 125 (CA₁₂₅), transforming growth factor (TNF)-α, and soluble interleukin-2 receptor (SIL-2R) in research group were better than those in control group, and there were significant differences (t=5.14, 6.53, 5.86; P<0.05). Total incidence of adverse reactions of chemotherapy in research group was remarkably lower than that in control group, overall effective rate of chemotherapy in research group was much higher than that in control group, and all the differences were statistically significant (χ²=4.44, 5.52; P<0.05).

Chemotherapy sensitivity in treatment of EOC with paclitaxel combined with cisplatin is much higher than the treatment with paclitaxel alone, and total incidence of adverse reaction is remarkably lower, and overall effective rate of chemotherapy is much higher than the treatment with paclitaxel alone. Whether positive expressions of GST-π and P170 glycoprotein as a judging criteria of overall effective in treatment of EOC are worthy of clinical application or not, multi-center and large-sample randomized controlled trial will be needed to confirm.